Effectiveness of 2024-2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes - IVY Network, 26 Hospitals, September 1, 2024-April 30, 2025.

ABSTRACT:

Importance

As SARS-CoV-2 JN.1 lineage descendants continue to evolve, evaluating COVID-19 vaccine effectiveness (VE) against severe COVID-19 is necessary to inform vaccine composition updates.

Objective

To estimate effectiveness of 2024-2025 COVID-19 vaccines against COVID-19-associated hospitalizations and severe in-hospital outcomes overall and by time since dose (7-89, 90-179, and ≥180 days), JN.1 descendant lineage (KP.3.1.1, XEC, LP.8.1), and spike mutations potentially associated with immune evasion.

Design setting and participants

This test-negative, case-control analysis included adult patients hospitalized during September 1, 2024-April 30, 2025 at 26 hospitals in 20 U.S. states. Cases presented with COVID-19-like illness and a positive SARS-CoV-2 nucleic aci

SUBMITTER: Ma KC 

PROVIDER: S-EPMC12424867 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature